» Articles » PMID: 38667278

Metabolic Alteration Bridging the Prediabetic State and Colorectal Cancer

Overview
Journal Cells
Publisher MDPI
Date 2024 Apr 26
PMID 38667278
Authors
Affiliations
Soon will be listed here.
Abstract

Prediabetes and colorectal cancer (CRC) represent compelling health burdens responsible for high mortality and morbidity rates, sharing several modifiable risk factors. It has been hypothesized that metabolic abnormalities linking prediabetes and CRC are hyperglycemia, hyperinsulinemia, and adipokines imbalance. The chronic stimulation related to these metabolic signatures can favor CRC onset and development, as well as negatively influence CRC prognosis. To date, the growing burden of prediabetes and CRC has generated a global interest in defining their epidemiological and molecular relationships. Therefore, a deeper knowledge of the metabolic impairment determinants is compelling to identify the pathological mechanisms promoting the onset of prediabetes and CRC. In this scenario, this review aims to provide a comprehensive overview on the metabolic alterations of prediabetes and CRC as well as an overview of recent preventive and therapeutic approaches for both diseases, focusing on the role of the metabolic state as a pivotal contributor to consider for the development of future preventive and therapeutic strategies.

Citing Articles

SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells.

Anastasio C, Donisi I, Del Vecchio V, Colloca A, Mele L, Sardu C Cell Mol Biol Lett. 2024; 29(1):80.

PMID: 38811901 PMC: 11134909. DOI: 10.1186/s11658-024-00599-1.

References
1.
Okada J, Yamada E, Saito T, Yokoo H, Osaki A, Shimoda Y . Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. Molecules. 2020; 25(3). PMC: 7038111. DOI: 10.3390/molecules25030495. View

2.
Sugiura K, Okabayashi K, Seishima R, Ishida T, Shigeta K, Tsuruta M . Metformin inhibits the development and metastasis of colorectal cancer. Med Oncol. 2022; 39(9):136. DOI: 10.1007/s12032-022-01722-y. View

3.
Cirillo F, Catellani C, Sartori C, Lazzeroni P, Amarri S, Street M . Obesity, Insulin Resistance, and Colorectal Cancer: Could miRNA Dysregulation Play A Role?. Int J Mol Sci. 2019; 20(12). PMC: 6628223. DOI: 10.3390/ijms20122922. View

4.
Dmitrieva-Posocco O, Wong A, Lundgren P, Golos A, Descamps H, Dohnalova L . β-Hydroxybutyrate suppresses colorectal cancer. Nature. 2022; 605(7908):160-165. PMC: 9448510. DOI: 10.1038/s41586-022-04649-6. View

5.
Wang W, Wei R, Huang Z, Luo J, Pan Q, Guo L . Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2023; 39(7):e3680. DOI: 10.1002/dmrr.3680. View